Role of [131I]metaiodobenzylguanidine therapy in medullary thyroid carcinoma
Hoefnagel, C.A.; Delprat, C.C.; Valdés Olmos, R.A.
Journal of Nuclear Biology and Medicine 35(4): 334-336
1991
ISSN/ISBN: 0368-3249 PMID: 1823851 Document Number: 4559
In recent years several radiopharmaceuticals have become available, offering new possibilities for the diagnosis and therapy of medullary thyroid carcinoma (MTC). For the diagnosis and follow-up 201TI-chloride and 99mTc(V)-DMSA are the tracers of choice. Imaging with [131I]metaiodobenzylguanidine (131I-MIBG) and 131I-anti-CEA or anti-calcitonin antibodies or fragments is less sensitive but very specific. These tracers can be used to evaluate their potential therapeutic use. Cumulative reported data on the diagnostic use of 131I-MIBG in 178 MTC patients indicate that overall 34.5% of medullary cancers concentrate MIBG. At The Netherlands Cancer Institute 131I-MIBG scintigraphy was positive in 8 of 23 patients with MTC. Four of these patients have received therapeutic amounts of 131I-MIBG, resulting in 1 partial remission and meaningful palliation in 3 patients with metastatic MTC. It is concluded that, although the preliminary experience suggests that the objective response of MTC to 131I-MIBG therapy is limited, the palliation provided to these patients, for whom there is little other treatment, may be very meaningful.
Document emailed within 1 workday
![Role of [131I]metaiodobenzylguanidine therapy in medullary thyroid carcinoma](https://img.popline.org/4559.webp)